Emisphere Technologies Inc., of Tarrytown, N.Y., appointed Alan Dunton president and chief operating officer.
Exelixis Inc., of South San Francisco, added Jane Green as vice president, corporate communications.
Insmed Inc., of Richmond, Va., appointed Fredrick Dunn vice president of clinical development.
IntraBiotics Pharmaceuticals Inc., of Mountain View, Calif., appointed Eric Bjerkholt senior vice president and chief financial officer.
Kos Pharmaceuticals Inc., of Miami, appointed Christopher Kiritsy senior vice president and chief financial officer, Mark McGovern senior vice president and chief medical officer, Fred Sexton senior vice president of technical operations and product development, and Christopher Rieder vice president of information technology.
Lexicon Genetics Inc., of The Woodlands, Texas, named Stephen McAndrew vice president of pharmaceutical business development.
Maxim Pharmaceuticals Inc., of San Diego, added Philippe Prokocimer as vice president, drug development.
Microbia Inc., of Cambridge, Mass., named John Talley vice president, drug discovery, and added Elias Corey to its scientific advisory board.
Milkhaus Laboratory Inc., of Providence, R.I., appointed Stephen Mamber as director of research.
Mologen Holding AG, of Berlin, added Guido Sandler as vice chairman of the board.
Panacea Pharmaceuticals Inc., of Rockville, Md., appointed Frank Young to its board.
Ricerca LLC, of Concord, Ohio, appointed William Kerns to its scientific advisory board.
Scil Biomedicals GmbH, of Martinsried, Germany, appointed Andreas Schuetz vice president of pharmaceutical technology.
Seattle Genetics Inc., of Bothell, Wash., appointed Bruce Blazar to its scientific advisory board.
VitaGen Inc., of La Jolla, Calif., appointed Mark D’Andrea vice president of manufacturing.
Xenon Genetics Inc., of Vancouver, British Columbia, appointed Gilbert Kliman to its board.
ZymoGenetics Inc., of Seattle, appointed Mark Young senior vice president, technical operations.